CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-22 | Booth Bruce Director | Sale 10b5-1 | −1,253 | $102.48 | $128K | 617,663 |
| 2026-06-22 | Goodman Noah Chief Business Officer | Option exercise 10b5-1 | +2,500 | $21.05 | $53K | 52,695.44 |
| 2026-06-22 | Goodman Noah Chief Business Officer | Sale 10b5-1 | −2,500 | $99.00 | $248K | 50,195.44 |
| 2026-06-22 | Goodman Noah Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,500 | 95,000 | ||
| 2026-06-18 | Booth Bruce Director | Sale 10b5-1 | −62,897 | $90.48 | $5.7M | 3,744,763 |
| 2026-06-18 | Booth Bruce Director | Sale 10b5-1 | −32,359 | $91.85 | $3.0M | 3,712,404 |
| 2026-06-18 | Booth Bruce Director | Sale 10b5-1 | −5,672 | $92.16 | $523K | 3,706,732 |
| 2026-06-18 | Booth Bruce Director | Sale 10b5-1 | −8,809 | $90.48 | $797K | 653,233 |
| 2026-06-18 | Booth Bruce Director | Sale 10b5-1 | −4,526 | $91.85 | $416K | 648,707 |
| 2026-06-18 | Booth Bruce Director | Sale 10b5-1 | −793 | $92.16 | $73K | 647,914 |
| 2026-06-17 | Booth Bruce Director | Option exercise 10b5-1 | +11,741 | $20.00 | $235K | 11,741 |
| 2026-06-17 | Booth Bruce Director | Sale 10b5-1 | −11,741 | $89.98 | $1.1M | 0 |
| 2026-06-17 | Booth Bruce Director | Sale 10b5-1 | −92,169 | $90.38 | $8.3M | 3,807,660 |
| 2026-06-17 | Booth Bruce Director | Sale 10b5-1 | −12,902 | $90.38 | $1.2M | 662,042 |
| 2026-06-17 | Booth Bruce Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,741 | 28,127 | ||
| 2026-06-02 | Jacobs Bruce N. Chief Financial Officer | Option exercise | +12,653 | $2.08 | $26K | 260,241 |
| 2026-06-02 | Jacobs Bruce N. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −12,653 | 0 | ||
| 2026-05-27 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −3,679 | $81.50 | $300K | 44,618 |
| 2026-05-27 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −600 | $82.08 | $49K | 44,018 |
| 2026-05-26 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −3,730 | $78.36 | $292K | 57,472 |
Page 10 of 25 · 493 trades